AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31

AGIOS PHARMACEUTICALS, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$34.90+3.58 (+11.43%)

Close on Oct 19, 2026

Market cap: $2.08B
P/E (TTM): –
Dividend yield: –

AGIOS PHARMACEUTICALS, INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	TTM Q2 2026 2026-06-30	TTM Q1 2026 2026-03-31	TTM FY 2025 2025-12-31	TTM Q3 2025 2025-09-30	TTM Q2 2025 2025-06-30	TTM Q1 2025 2025-03-31	TTM FY 2024 2024-12-31	TTM Q3 2024 2024-09-30	TTM Q2 2024 2024-06-30	TTM Q1 2024 2024-03-31	TTM FY 2023 2023-12-31	TTM Q3 2023 2023-09-30	TTM Q2 2023 2023-06-30	TTM Q1 2023 2023-03-31	TTM FY 2022 2022-12-31	TTM Q3 2022 2022-09-30	TTM Q2 2022 2022-06-30	TTM Q1 2022 2022-03-31	TTM FY 2021 2021-12-31	TTM Q3 2021 2021-09-30	TTM Q2 2021 2021-06-30	TTM Q1 2021 2021-03-31	TTM FY 2020 2020-12-31	TTM Q3 2020 2020-09-30	TTM Q2 2020 2020-06-30	TTM Q1 2020 2020-03-31	TTM FY 2019 2019-12-31	TTM Q3 2019 2019-09-30	TTM Q2 2019 2019-06-30	TTM Q1 2019 2019-03-31	TTM FY 2018 2018-12-31	TTM Q3 2018 2018-09-30	TTM Q2 2018 2018-06-30	TTM Q1 2018 2018-03-31	TTM FY 2017 2017-12-31	TTM Q3 2017 2017-09-30	TTM Q2 2017 2017-06-30	TTM Q1 2017 2017-03-31	TTM FY 2016 2016-12-31	TTM Q3 2016 2016-09-30
Revenue	98	66	54	45	41	37	36	33	31	29	27	24	20	19	14	9.93	6.41	0.83	0	44	79	116	0	195	186	175	118	112	102	116	94	74	70	41	43	56	53	49	70	53
Cost of Revenue	7.87	6.58	6.35	5.73	4.83	4.62	4.17	3.49	3.34	2.95	2.88	2.71	2.59	1.92	1.70	1.29	0.77	0.34	0	0.96	1.60	2.27	0	2.13	1.89	1.52	1.32	1.73	2.03	1.73	1.40	0.70	0	–	0	–	–	–	–	–
Gross Profit	90	59	48	39	36	32	32	29	28	26	24	21	18	17	13	8.64	5.64	0.49	0	43	77	114	0	192	184	173	117	111	100	114	93	73	70	–	43	–	–	–	–	–
Research & Development	357	348	340	334	320	305	301	296	305	297	296	288	271	277	280	283	282	269	257	243	231	223	221	268	317	371	214	398	379	359	341	325	315	308	293	280	268	239	220	192
Selling, General & Admin	193	187	180	180	178	167	157	140	128	123	120	117	121	119	122	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	105	91	81	71	64	58	55	51	46
Operating Expenses	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	529	509	482	457	430	406	389	364	344	326	294	271	238
Total Costs & Expenses	557	542	526	520	502	477	462	440	436	422	418	408	395	398	403	405	401	389	378	359	348	340	336	164	219	276	316	–	–	–	–	–	–	–	–	–	–	–	–	–
Operating Income	-459	-476	-472	-476	-462	-440	-426	-407	-405	-393	-391	-384	-375	-379	-389	-395	-395	-388	-378	-366	-355	-347	-336	-357	-385	-416	-316	-417	-407	-366	-362	-356	-336	-348	-321	-288	-273	-244	-201	-184
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	4.02	6.61	9.40	11	13	15	16	17	18	16	14	11	8.43	6.12	5.20	4.00	3.00	2.51	1.87
Other Non-Operating Income	0.42	0.82	1.96	3.47	5.05	6.11	6.49	6.58	6.12	6.19	6.06	5.70	5.58	5.28	6.75	8.66	12	17	14	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–
Gain (Loss) on Sale of Assets	–	–	-0.01	-0.01	200	200	0.04	200	-0.24	-0.24	-0.55	0.23	4.67	7.37	0.05	7.14	4.70	3.99	-0.01	4.00	2.00	–	0	–	–	–	-1.05	–	–	–	-0.02	0.02	0.02	0	-0.04	-0.04	-0.04	–	0	–
Pretax Income	–	–	-414	–	–	–	718	–	–	–	-352	–	–	–	–	–	–	–	-357	-342	-337	-336	-329	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income Tax Expense	–	–	-1.02	–	–	–	44	–	–	–	0	–	–	–	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	0	0
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-232	-367	-369	-360	-357	-342	-337	-336	-329	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	0	3.96	-0.55	-3.98	1,961	1,944	1,929	1,923	1.94	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Net Income	-411	-423	-413	-401	650	666	674	674	-365	-353	-352	-220	-210	-218	-232	-363	-370	-364	1,605	1,602	1,591	1,587	-327	-332	-339	-359	-411	-401	-389	-348	-346	-343	-325	-339	-315	-250	-235	-208	-198	-183
Net Income to Common	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1,605	1,602	1,591	1,587	-327	-332	-339	-359	-411	-401	-389	-348	-346	-343	-325	-339	-315	-283	-269	-241	-198	-183
EPS (Basic)(per share)	-7.01	-7.25	-7.12	-6.95	11.48	11.72	11.86	11.79	-6.50	-6.32	-6.33	-3.96	-3.81	-3.98	-4.23	-6.65	-6.72	-6.45	26.55	22.57	22.70	22.80	-4.74	-4.93	-5.31	-5.87	-6.86	-6.85	-6.67	-5.99	-6.03	-6.26	-6.22	-6.81	-6.75	-6.27	-6.31	-6.00	-5.07	-4.79
EPS (Diluted)(per share)	-7.01	-7.25	-7.12	-6.90	11.10	11.34	11.64	11.36	-6.50	-6.32	-6.33	-3.96	-3.81	-3.98	-4.23	-6.65	-6.72	-6.45	26.55	22.57	22.70	22.80	-4.74	-4.93	-5.31	-5.87	-6.86	-6.85	-6.67	-5.99	-6.03	-6.26	-6.22	-6.81	-6.75	-6.27	-6.31	-6.00	-5.07	-4.79
Shares Outstanding (Basic, Weighted)(shares)	59	58	58	58	57	57	57	57	56	56	56	55	55	55	55	55	55	57	60	64	67	69	69	68	65	63	60	59	58	58	57	55	53	50	47	45	42	40	39	38
Shares Outstanding (Diluted, Weighted)(shares)	59	58	58	58	58	58	58	57	56	56	56	55	55	55	55	55	55	57	60	64	67	69	69	68	65	63	60	59	58	58	57	55	53	50	47	45	42	40	39	38

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 92.0%
Operating margin: -466.8%
Net margin: -418.2%
Return on equity, FY2025: -30.2%

Financial strength

Current ratio: 10.22
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.9%

Valuation

P/E ratio: –
Price to sales: 21.11
Price to book: 2.02
Dividend yield: –